12:00 AM
Apr 25, 2005
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Thymitaq nolatrexed: Completed Phase III enrollment

Eximias completed enrollment of 446 patients in the open-label, international Phase III ETHECC trial. Thymitaq, which has Fast Track and Orphan designations,...

Read the full 87 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >